Enliven Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

ELVN$51.20-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance - January 1, 2024	41,292,027	$41	$400,172	$141	$(154,448)	$245,906
Exercise of common stock options	130,780	—	320	—	—	320
Vesting of restricted stock units	2,688	—	—	—	—	—
Vesting of restricted stock awards and stock options	—	—	73	—	—	73
Issuance of common stock and pre-funded warrants in the Private Placement, net of issuance costs of $170	5,357,144	6	89,824	—	—	89,830
Stock-based compensation	—	—	4,515	—	—	4,515
Net loss	—	—	—	—	(22,738)	(22,738)
Other comprehensive loss	—	—	—	(194)	—	(194)
Balance - March 31, 2024	46,782,639	$47	$494,904	$(53)	$(177,186)	$317,712
Exercise of common stock options	357,277	—	1,859	—	—	1,859
Vesting of restricted stock units	1,749	—	—	—	—	—
Vesting of restricted stock awards and stock options	—	—	68	—	—	68
Issuance of common stock under the ESPP	31,801	—	320	—	—	320
Issuance costs related to the Private Placement	—	—	(135)	—	—	(135)
Stock-based compensation	—	—	5,144	—	—	5,144
Net loss	—	—	—	—	(19,950)	(19,950)
Other comprehensive loss	—	—	—	(86)	—	(86)
Balance - June 30, 2024	47,173,466	$47	$502,160	$(139)	$(197,136)	$304,932
Exercise of common stock options	79,063	—	1,004	—	—	1,004
Vesting of restricted stock units	1,751	—	—	—	—	—
Vesting of restricted stock awards and stock options	—	—	66	—	—	66
Stock-based compensation	—	—	5,176	—	—	5,176
Net loss	—	—	—	—	(23,156)	(23,156)
Other comprehensive income	—	—	—	381	—	381
Balance - September 30, 2024	47,254,280	$47	$508,406	$242	$(220,292)	$288,403

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

Common Stock · Additional Paid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance - January 1, 2025	48,936,459	$49	$553,213	$55	$(243,472)	$309,845
Exercise of common stock options	91,915	—	234	—	—	234
Vesting of restricted stock units	10,356	—	—	—	—	—
Vesting of stock options	—	—	33	—	—	33
Stock-based compensation	—	—	6,799	—	—	6,799
Net loss	—	—	—	—	(28,544)	(28,544)
Other comprehensive loss	—	—	—	(71)	—	(71)
Balance - March 31, 2025	49,038,730	$49	$560,279	$(16)	$(272,016)	$288,296
Exercise of common stock options	236,893	—	1,324	—	—	1,324
Vesting of restricted stock units	6,604	—	—	—	—	—
Vesting of stock options	—	—	28	—	—	28
Issuance of common stock under the ESPP	22,957	—	427	—	—	427
Issuance of common stock and pre-funded warrants in the Public Offering, net of issuance costs of $13,875	9,920,987	10	216,159	—	—	216,169
Stock-based compensation	—	—	7,724	—	—	7,724
Net loss	—	—	—	—	(25,335)	(25,335)
Other comprehensive loss	—	—	—	(161)	—	(161)
Balance - June 30, 2025	59,226,171	$59	$785,941	$(177)	$(297,351)	$488,472
Exercise of common stock options	28,507	—	209	—	—	209
Vesting of restricted stock units	6,608	—	—	—	—	—
Vesting of stock options	—	—	6	—	—	6
Stock-based compensation	—	—	7,185	—	—	7,185
Net loss	—	—	—	—	(20,148)	(20,148)
Other comprehensive income	—	—	—	398	—	398
Balance - September 30, 2025	59,261,286	$59	$793,341	$221	$(317,499)	$476,122

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.